कंपनी का अवलोकन
Zymeworks Inc. is a biotechnology enterprise dedicated to developing biotherapeutics designed for the treatment of cancer, inflammation, and autoimmune diseases. The company operates within the healthcare sector, specifically functioning in the biotechnology industry, which focuses on the discovery, development, and commercialization of advanced medical treatments. As of the latest data, the organization employs 264 individuals and holds a market capitalization of $1.98B, with reported annual revenue of $105.97M. These valuation and revenue figures indicate that Zymeworks Inc. occupies a significant position within the biotechnology landscape, commanding a substantial market value despite the high-risk nature of the industry. The scale of the company, reflected in its nearly $2B market cap, suggests strong investor interest and confidence in its proprietary platforms, including the Azymetric multispecific antibody platform and Drug Conjugate platform.
वित्तीय स्वास्थ्य
Zymeworks Inc. reported a revenue of $105.97M for the trailing twelve months, yet this generated a net income of $-81,130,000 and an EBITDA of $-84,824,000. The substantial gap between the positive revenue figure and the deeply negative net income reveals a highly aggressive cost structure where operating expenses significantly outpace gross revenue generation. The company reported a free cash flow of $-12,959,125, indicating that current cash burn is being utilized to fund research and development activities rather than returning capital to shareholders. In terms of profitability margins, the gross margin stands at -29.3%, while the operating margin is -1755.5% and the profit margin is -76.6%, all of which indicate that the company is currently operating at a loss on an absolute basis. Regarding the balance sheet, the company holds $228.80M in cash against $18.27M in debt, resulting in a debt-to-equity ratio of 6.80, which suggests a highly leveraged position relative to equity, though the substantial cash reserve provides a buffer. The current ratio of 5.88 indicates robust short-term liquidity, meaning the company possesses more than five times the current assets required to cover its short-term liabilities. Furthermore, the return on equity is -26.7% and the return on assets is -14.3%, metrics that reveal that management is currently generating negative returns on both shareholder equity and the total asset base due to the pre-commercialization stage of the business.
मूल्यांकन आकलन
The valuation metrics present a complex picture, with a trailing P/E ratio marked as N/A due to the lack of net income, while the forward P/E is listed at 33.93. The absence of a trailing P/E and the existence of a forward P/E imply that the market is pricing the stock based on future anticipated earnings rather than historical profitability, a common characteristic of biotechnology firms awaiting product approvals. The price-to-book ratio is 7.43, indicating that the market values the company at a significant premium over its book value, reflecting the high valuation placed on its intellectual property and pipeline potential. Additionally, the price-to-sales ratio is 18.73, and the EV/EBITDA is -20.74, suggesting that traditional earnings-based valuation models are not applicable, and investors are relying on revenue multiples to assess value. The stock has traded between a 52-week low of $9.03 and a 52-week high of $28.49. Based on the 52-week range, the current trading price sits significantly below the high, reflecting the volatility and uncertainty inherent in the sector. The beta is 1.20, which means the stock price is expected to be 20% more volatile than the broader market, amplifying both potential gains and losses relative to the S&P 500.
Growth & Income
Zymeworks Inc. experienced a revenue growth of -91.9% year-over-year, while earnings growth is N/A due to the company's continued losses. The negative revenue growth indicates a contraction in sales compared to the previous year, which is a critical metric for assessing the current commercial performance of the company's product portfolio. Since the company does not pay dividends, with a dividend yield of N/A and a payout ratio of 0.0%, it operates as a non-dividend payer that reinvests all available earnings and cash reserves into research, development, and operational expansion. Consequently, the overall growth and income profile is characterized by negative revenue growth and zero income distribution, prioritizing capital expenditure for long-term asset creation over immediate shareholder returns.